Providers/Grant Support
This activity is supported by an independent education grant from Lilly.
Credits Available
This activity does not offer credit.
Target Audience
This activity is designed to meet the educational needs of Imaging physicians, including Nuclear Medicine Physicians, Radiologists, Neuroradiologists, Radiology Physician Assistants, Imaging Residents. It is also suitable for Neurologists.
Program Overview
As the landscape of Alzheimer’s disease continues to evolve, PET imaging is playing an increasingly critical role in early and accurate diagnosis, disease staging, and treatment decision-making. But how can nuclear medicine and radiology physicians effectively integrate PET imaging into clinical practice while navigating regional variations, emerging tracers, and evolving guidelines?
This activity will cover the latest insights, practical strategies, and real-world case studies on PET imaging in Alzheimer’s disease. Featuring leading experts from Europe, Asia, and the USA, this program will provide a global perspective on best practices, challenges, and decision-making tools to optimize patient care.
Put your decision-making and interpretation skills into practice in a simulated environment. Presented with different patient characteristics, you will be challenged to choose the optimal tracer, accurately interpret the results, and advise on next steps.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Integrate best practice for the selection, interpretation, and reporting of PET biomarkers in the context of your local clinical practice
- Incorporate optimal communication and reporting methods to enhance interdisciplinary working and patient relationships
Faculty
Prof Alexander Drzezga
Chair of the Department of Nuclear Medicine
University Hospital of Cologne, Germany
Alexander Drzezga studied human medicine at the Ludwig Maximilians University and the Technical University of Munich, obtained a license for medical practice, and took up residency at the Department of Nuclear Medicine of the Technical University of Munich.
In 2002 Drzezga specialized in nuclear medicine, and was a Consultant at the Department before becoming Assistant Professor at the Technical University. Since 2012 he has been Professor and Chair of the Department of nuclear medicine at the University Hospital Cologne, and he is currently the chair of the Department of Nuclear Medicine at the University Hospital Cologne and affiliated with the German Center for Neurodegenerative Disorders (DZNE) and the Institute for Neuroscience and Medicine (INM) at the Research Center Juelich. In 2018 he became Director at the INM.
Drzezga’s research focus is on the application of multimodal and molecular imaging procedures to investigate neurodegenerative disorders and their interrelation to the network architecture of the brain. He is a member of the AMYPAD project and is a Principal Investigator at the AMYPAD site in Cologne, Germany.
Disclosures of Conflicts of Interest
Prof Alexander Drzezga
Disclosures
Grant funding and research support from, Sofie, Novartis/AAA, and Deutsche Forschungsgesellschaft, DFG, BMBF, Juelich, Wellcome Leap, Bayer Vital, European Research Council, Invicros, Biogen, GE Healthcare; and honoraria or consulting fees from GE Healthcare, Biogen, Novartis, Lilly, Siemens Healthineers, Springer Healthcare, Lilly Deutschland, Peer View Institute for Medical Education Inc., Bayer Vital GmbH, Invicro, and International Atomic Energy Agency, Swiss Rockets.
Stocks, shares or equity in Siemens Healthineers, Lantheus Holding, Structured Therapeutics, Lilly. In addition he has applied for patent for 2-Alkoxy-6-[18F]Fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues (Patent No.: EP3765097A1).
Other financial or material support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, Eisai, Sofie, Ariceum Therapeutics, AVID.
Instructions for Participation
There are no fees for participating in this enduring activity. Read the information and faculty disclosures, participate in this online activity, and submit the evaluation form.
Disclosure of Unlabeled Use
Faculty participating in any CME activity are required to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For questions please contact [email protected]